Testing strategy for laboratory monitoring of Hemophilia A patients treated with Emicizumab

被引：0
|
作者：
Pikta, M. [1 ]
Saks, K. [4 ]
Ross, M. [3 ]
Banys, V. [2 ]
机构：
[1] Tallinn Univ Technol, Dept Hlth Technol, Dept Lab Med, North Estonia Med Ctr, Tallinn, Estonia
[2] Vilnius Univ, Inst Biomed Sci, Dept Physiol Biochem Microbiol & Lab Med, Fac Med, Vilnius, Lithuania
[3] North Estonia Med Ctr, Dept Hematol, Tallinn, Estonia
[4] Tallinn Childrens Hosp, Dept Hematol, Tallinn, Estonia
来源：
CLINICA CHIMICA ACTA | 2022年 / 530卷
关键词：
D O I：
10.1016/j.cca.2022.04.750
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
T262
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [41] Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National US Survey
    Al-Samkari, Hanny
    Croteau, Stacy E.
    BLOOD, 2019, 134
  • [42] Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Ballester, Lance
    Raffini, Leslie J.
    BLOOD, 2019, 134
  • [43] Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience
    Giuffrida, Gaetano
    Nicolosi, Daniela
    Condorelli, Annalisa
    Markovic, Uros
    Di Raimondo, Francesco
    BLOOD, 2021, 138
  • [44] Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US
    Owens, Wendy E.
    Patel, Anisha M.
    Poulos, Kathleen
    Bernard, Janet
    Powers, Janet
    Ko, Richard H.
    BLOOD, 2019, 134
  • [45] Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3
    Kiialainen, Anna
    Niggli, Markus
    Kempton, Christine L.
    Castaman, Giancarlo
    Chang, Tiffany Y.
    Paz-Priel, Ido
    Adamkewicz, Joanne I.
    Levy, Gallia G.
    BLOOD, 2019, 134
  • [46] VERIFICATION AND COMPARISON OF CHROMOGENIC FVIII ASSAY IN HEMOPHILIA PATIENTS WITH/WITHOUT EMICIZUMAB
    Lee, MinYoung
    Lee, Woo In
    Kang, So Young
    Kim, Myeong Hee
    Park, Young Shil
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 102 - 103
  • [47] Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Guerrera, Michael F.
    Massey, Gita
    Raffini, Leslie J.
    BLOOD, 2019, 134
  • [48] Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
    Levy-Mendelovich, Sarina
    Atia, Nitzan
    Budnik, Ivan
    Barg, Assaf Arie
    Msc, Einat Avishai
    Cohen, Omri
    Brutman-Barazani, Tami
    Livnat, Tami
    Kenet, Gili
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (04)
  • [49] LABORATORY TESTING IN DIRECT FACTOR INHIBITORS TREATED PATIENTS
    Vavilova, Tatiana
    Bekoeva, Angela
    Zubkova, Polina
    Skorobogatova, Yulia
    Yurinok, Irina
    Vasilieva, Elena
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 113 - 114
  • [50] MANAGEMENT OF A TOTAL KNEE ARTHROPLASTY IN A SEVERE HEMOPHILIA A PATIENT TREATED WITH EMICIZUMAB: AN EXPERIMENT IN STRASBOURG
    Sattler, L.
    Herb, A.
    Feugeas, O.
    Dumoussaud, N.
    Gerout, A. -C.
    Boeri, C.
    Desprez, D.
    HAEMOPHILIA, 2020, 26 : 93 - 93
12345